Cell-based therapies hold the potential to alleviate the growing burden of liver diseases. Such therapies require human hepatocytes, which, within the stromal context of the liver, are capable of many rounds of replication. However, this ability is lost ex vivo, and human hepatocyte sourcing has limited many fields of research for decades. Here we developed a high-throughput screening platform for primary human hepatocytes to identify small molecules in two different classes that can be used to generate renewable sources of functional human hepatocytes. The first class induced functional proliferation of primary human hepatocytes in vitro. The second class enhanced hepatocyte functions and promoted the differentiation of induced pluripotent stem cell–derived hepatocytes toward a more mature phenotype than what was previously obtainable. The identification of these small molecules can help address a major challenge affecting many facets of liver research and may lead to the development of new therapeutics for liver diseases. Chronic liver disease affects more than 500 million people worldwide 1. Most treatments are palliative; the only therapy shown to directly alter outcome and prevent mortality is organ transplantation, but its utility is limited by a persistent shortage of donor organs 2. Cell-based therapies, such as cell transplantation, engineered hepatocellular tissue constructs and bioartificial live
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.